Three things drive most of it. Blood vessels: the arteries feeding an erection are one to two millimeters wide, the ones feeding the heart three to four. Artery narrowing hits the smallest first, so the bedroom fails years before the chest does 1. Hormones: after menopause, falling estrogen thins vaginal tissue and it keeps worsening untreated 2. Other people's drugs: the most common antidepressants (SSRIs) cause sexual side effects in most people who take them, once someone actually asks 3.
The erection is a stress test you didn't book. Across fourteen cohorts, men with erectile dysfunction had a 44% higher rate of cardiovascular events, strongest in men forty to sixty, with a typical three-to-five-year lead time before the heart trouble arrives 1. So a man under seventy whose erections change needs a heart workup before a sildenafil script.
Almost every problem here has cheap, proven treatment. Erection pills restore intercourse from about a quarter of attempts to two-thirds, and generic sildenafil now costs pennies a dose 4. For women, local vaginal estrogen rebuilds the tissue in four to twelve weeks with essentially none reaching the bloodstream, yet fewer than one in ten who need it get it 5. The barrier is conversational: only 38% of men and 22% of women have ever raised sex with a clinician after fifty 6.
The whole game is one conversation you keep not having.
The arc, once you raise it:
- Weeks: the pill or the cream works, and the relief of learning it wasn't you is bigger than the function itself.
- Six weeks: for women on local estrogen, the tissue rebuilds and sex stops hurting 5.
- First year: the workup finds the borderline cholesterol; walking and diet pull it back into range 7.
- A decade: peers start having heart attacks and you don't, because the bedroom trouble sent you to a cardiologist at fifty-five instead of an ambulance at sixty-five.
The fine print — when to skip it, and what people get wrong
"Low desire in later life is just normal aging." It's common but rarely inevitable, and rarely raised 6. "Testosterone gets an aging man's edge back." Only about 2% of men forty to seventy-nine truly meet the criteria; most low levels reverse when the real cause is treated 8. "Hormone therapy causes breast cancer and heart attacks." For women under sixty or within ten years of menopause, the long-term data is reassuring 9. "Older adults don't get STIs." Rates are rising fastest in the over-fifty-fives 10.
Almost everything here is clinician-managed. Never combine erection pills with nitrates ("poppers," nitroglycerin, isosorbide) — the drop in blood pressure can be lethal. Defer sex after a recent heart attack or with unstable angina until a cardiologist clears you.
An erection pill that "didn't work" usually means too low a dose, too little arousal, or a heavy meal blunting it; true non-response earns a urology visit. Vaginal estrogen that "didn't work" usually means two weeks tried instead of eight 5.
- 1Vlachopoulos CV et al. (2013). Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: a systematic review and meta-analysis of cohort studies. Circulation: Cardiovascular Quality and Outcomes. link
- 2Portman DJ, Gass ML (2014). Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Menopause. link
- 3Montejo AL et al. (2001). Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Journal of Clinical Psychiatry. link
- 4Goldstein I et al. (1998). Oral sildenafil in the treatment of erectile dysfunction. New England Journal of Medicine. link
- 5Lethaby A et al. (2016). Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database of Systematic Reviews. link
- 6Lindau ST et al. (2007). A study of sexuality and health among older adults in the United States. New England Journal of Medicine. link
- 7Esposito K et al. (2004). Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA. link
- 8Wu FCW et al. (2010). Identification of late-onset hypogonadism in middle-aged and elderly men. New England Journal of Medicine. link
- 9Manson JE et al. (2017). Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women's Health Initiative randomized trials. JAMA. link
- 10CDC (2023). Sexually Transmitted Infections Surveillance, 2022. link
Sexual Health in Aging
Generic sildenafil and tadalafil ~$1–2 per dose; low-dose vaginal estrogen $30–100/month and generally insured; testosterone gel ~$30–80/month generic. Lifestyle interventions free. Most reader-relevant action sits under $500/year.
Hardest step is raising the topic with a clinician once. After that: small daily lifestyle measures already counted elsewhere, occasional medication adherence, periodic clinical follow-up. Sub-15-minute marginal daily cost.
Multiple meta-analyses (Vlachopoulos et al. 2013 on ED–CVD; Holt-Lunstad et al. 2010 on social connection; Lethaby et al. 2016 Cochrane on local estrogen), pivotal RCTs (Goldstein et al. 1998 sildenafil; Snyder et al. 2016 testosterone; Manson et al. 2017 WHI long-term; Esposito et al. 2004 lifestyle), and aligned current guidelines (NAMS 2022, AUA / Mulhall et al. 2018, Endocrine Society / Bhasin et al. 2018, BSSM / Hackett et al. 2018) across all major components.
PDE5 inhibitors restore intercourse success from ~22% to ~69% in pivotal RCTs (Goldstein et al. 1998); low-dose vaginal estrogen resolves dyspareunia and dryness within 4–12 weeks (Lethaby et al. 2016 Cochrane). The same ED workup that resolves the immediate complaint detects subclinical cardiovascular disease in the same window.
ED associates with 44% higher CVD events and 25% higher all-cause mortality, declaring 3–5 years before symptomatic CVD (Vlachopoulos et al. 2013 meta of 14 cohorts). Caerphilly cohort: highest orgasm-frequency tertile carried roughly half the 10-year mortality of the lowest (Davey Smith et al. 1997). Intimate partnership and social-connection mortality signal is comparable to smoking cessation (Holt-Lunstad et al. 2010 meta).
Sexual satisfaction and partnered intimacy correlate with reduced depression in NSHAP and parallel cohorts (Lindau et al. 2007). SSRI-induced sexual dysfunction at 58–73% prevalence prolongs depressive episodes (Montejo et al. 2001); switching agents resolves a meaningful fraction. The broader intimate-partnership and social-connection signal (Holt-Lunstad et al. 2010, 2015) applies to mental wellbeing as much as mortality.
Confirmed symptomatic hypogonadism is fatigue-driven; testosterone replacement modestly improves activity in the Testosterone Trials (Snyder et al. 2016) but the eligibility envelope is narrow (~2% of men 40–79 per EMAS; Wu et al. 2010). In women, treating GSM and vasomotor symptoms relieves sleep-disruption-driven daytime fatigue (NAMS 2022).
Vasomotor symptoms fragment sleep architecture and respond to MHT (NAMS 2022). GSM-driven nocturia improves on local estrogen (Lethaby et al. 2016). Orgasm produces post-coital prolactin and oxytocin release driving acute drowsiness.
Untreated SSRI-induced sexual dysfunction (58–73% prevalence per Montejo et al. 2001) prolongs the depressive symptom burden whose cognitive cost is well-documented. No direct cognitive mechanism; the lift is downstream of mood and sleep.